Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.
Journal: Blood advances
Published: October 24, 2023
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
Journal: The Lancet. Oncology
Published: August 03, 2023
Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study.
Journal: Endocrinology and metabolism (Seoul, Korea)
Published: September 23, 2020
Correction to: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
Journal: Journal of bone and mineral metabolism
Published: March 22, 2020
Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study.
Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Published: June 20, 2019
Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
Journal: Journal of bone and mineral metabolism
Published: May 16, 2019
Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Journal: Archives of osteoporosis
Published: March 01, 2019
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Published: February 19, 2019
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: May 18, 2018
Current unmet needs in renal transplantation: a review of challenges and therapeutics.
Journal: Frontiers in bioscience (Elite edition)
Published: December 29, 2015
Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates.
Journal: Clinical transplantation
Published: June 13, 2012
Transplant immunology for non-immunologist.
Journal: The Mount Sinai journal of medicine, New York
Published: June 09, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026